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The Journal of Immunology
LLT1 and CD161 Expression in Human Germinal Centers
Promotes B Cell Activation and CXCR4 Downregulation
Alba Llibre,* Constantino Lo´pez-Macı´as,†,1 Teresa Marafioti,‡,1 Hema Mehta,*
Amy Partridge,* Carina Kanzig,* Felice Rivellese,x Jacob D. Galson,{ Lucy J. Walker,‖
Paul Milne,‖ Rodney E. Phillips,* Dominic F. Kelly,{ Gordon J. Freeman,#
Mohey Eldin El Shikh,x Paul Klenerman,*,**,2 and Christian B. Willberg*,**,2
Germinal centers (GCs) aremicroanatomical structures critical for the development of high-affinity Abs and B cell memory. They are
organized into two zones, light and dark, with coordinated roles, controlled by local signaling. The innate lectin-like transcript 1
(LLT1) is known to be expressed on B cells, but its functional role in the GC reaction has not been explored. In this study, we report
high expression of LLT1 on GC-associated B cells, early plasmablasts, and GC-derived lymphomas. LLT1 expression was readily
induced via BCR, CD40, and CpG stimulation on B cells. Unexpectedly, we found high expression of the LLT1 ligand, CD161, on
follicular dendritic cells. Triggering of LLT1 supported B cell activation, CD83 upregulation, and CXCR4 downregulation. Overall,
these data suggest that LLT1–CD161 interactions play a novel and important role in B cell maturation within the GC in
humans. The Journal of Immunology, 2016, 196: 2085–2094.
T
hegerminal center (GC) reaction is critical for long-lasting
protection against pathogens. GCs are the anatomical sites
within secondary lymphoid organs where B cells prolif-
erate and mutate their BCRs to be selected according to their
affinity for Ag. Two distinct areas with different functions can be
identified within the GC; these are the dark zone (DZ) and the light
zone (LZ). In the former, B cells proliferate and hypermutate their
BCRs to generate Ab variation, whereas the quality of these BCRs
is assessed in the latter, ultimately leading to selection of high-
affinity B cell clones (1, 2). DZ B cells are characterized by
being CD83lowCXCR4high, whereas LZ B cells are CD83high
CXCR4low (3). B cells that have successfully competed for Ag
develop into clones and exit the GC expressing high-affinity Abs
and long-lived memory. Thus, this process is crucial to vaccinol-
ogy. At the same time, however, as a site of mutation and pro-
liferation, aberrant reactions can lead to the development of B cell
lymphomas and autoimmunity. Understanding the mechanisms
that drive this process has significant implications in health care.
C-type lectin-like receptors (CLRs) are encoded in the NK gene
complex (NKC) and can be expressed in a wide range of human cell
types, including NK cells. They are particularly relevant in the
context of innate immune responses. The CLRs lectin-like tran-
script 1 (LLT1) and CD161 are genetically linked physiological
binding partners, located adjacent to one another within the NKC
(4–7). Structurally, LLT1 shares the greatest homology with the
other C-type lectins activation-induced C-type lectin and CD69
(8). Within murine models, LLT1 shows a similar expression
pattern to MHC class I (9, 10), whereas in humans it is limited to
activated lymphocytes and monocytes (8, 11–13) and recently on
respiratory syncytial virus–infected primary human bronchial
epithelial cells (14), although the published literature presents
some inconsistencies. In contrast, the expression of LLT1’s
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binding partner, CD161, has been relatively well characterized,
delineating a family of innate-like T lymphocytes and NK cells
(15). Functional studies have described inhibitory and activating
roles for both molecules (6, 7, 15–23). These studies suggest that
interactions between LLT1 and CD161 can result in bidirectional
signaling and have functional consequences for both cells in-
volved.
In this study, we show the high expression of LLT1 on human GC
B cells and GC-derived B cell lymphomas, extending previous
studies (6, 8, 11–13, 17). We also show that LLT1 expression re-
mains on early plasmablasts, but is absent from memory B cells and
plasma cells. The LLT1 ligand, CD161, was found, unexpectedly,
on follicular dendritic cells (FDCs). Finally, triggering of LLT1
promoted the upregulation of CD83 on B cell and drives DZ B cells
toward a LZ phenotype through the downregulation of CXCR4.
Previously, LLT1 and CD161 were considered part of innate im-
mune responses. The present study demonstrates a functional role
for an innate receptor pairing at the heart of a critical adaptive
immune process, the GC reaction in humans.
Materials and Methods
Tissues, cells, and cell lines
Human tonsillar tissue was obtained following routine tonsillectomy
from the files of the Department of Cellular Pathology (University
College London Hospital, London, U.K.); Human Tissue Resource
Centre, Barts and the London National Health Service Trust, Queen
Mary School of Medicine and Dentistry; and from the Ear, Nose, and
Throat Department, John Radcliffe Hospital, Oxford, U.K. Normal
tonsillar tissue sections were obtained from ProteoGenix (Schiltigheim,
France). Tonsil-derived single cells were collected by mechanical dis-
ruption of tonsil samples or collagenase D (1 mg/ml; Boehringer
Mannheim) and DNase I (0.1 mg/ml; Sigma-Aldrich, Dorset, U.K.)
digestion, as stated. The lymphoma samples analyzed were in the form
of 0.6- to 1-mm core tissue arrays.
PBMCs obtained from the National Blood Transfusion Service (National
Health Service Blood and Transplant) were isolated on a Lymphoprep
gradient (Axis-Shield, Dundee, U.K.).
Bulk B cells were isolated by negative selections from PBMCs or tonsils
by magnetic isolation (Stemcell Technologies, Cambridge, U.K.) following
manufacturer’s protocols.
300.19-hCLEC2D cells were created by transfection of 300.19 with a
vector expressing human CD161/CLEC2D cDNA and maintained under
selection.
Vaccine samples were obtained from the Oxford Vaccine Group,
Churchill Hospital (Oxford, U.K.) following HBV vaccinations.
Bone marrow samples were obtained from routine hip joint operations
(Newcastle University, Newcastle upon Tyne, U.K.). Samples were filtered
(40 mm), washed with PBS, homogenized, isolated on a Lymphoprep
gradient (Axis-Shield) and aliquoted in FCS plus 10% DMSO (Sigma-
Aldrich) and stored in liquid nitrogen until required.
For sorted cells, DZ B cells were FACS sorted using a MoFlo XDP
(Beckman Coulter, High Wycombe, U.K.) from purified B cells and defined
as singlets, alive, CD38midIgD2CXCR4highCD83low cells.
Informed consent was obtained from all subjects.
In vitro differentiation of plasma cells
Memory B cells were differentiated in vitro into plasmablasts and plasma
cells, following the protocol described in Jourdan et al. (24). Briefly, CD27+
Memory B cells were first purified as bulk B cells by negative selection
from PBMCs by magnetic isolation followed by positive selection for
CD27+ cells (Stemcell Technologies) following the manufacturer’s pro-
tocol. The cells were then seeded at 1.53 105 cells/ml and cultured for 4 d
in the presence of CpG oligodeoxynucleotide 2006 (10 mg/ml; Invitrogen,
Paisley, U.K.), soluble human his-rCD40L (50 ng/ml; R&D Systems,
Abingdon, U.K.) and anti–poly-his (5 mg/ml; R&D Systems), IL-2 (20
U/ml; R&D Systems), IL-10 (50 ng/ml; Miltenyi Biotec, Surrey, U.K.),
and IL-15 (10 ng/ml; Miltenyi Biotec). At day 4 of culture, the cells were
washed and cultured at 2.5 3 105 cells/ml with IL-2 (20 U/ml; Miltenyi
Biotec), IL-10 (50 ng/ml), IL-15 (10 ng/ml; PeproTech, London, U.K.),
and IL-6 (50 ng/ml; Miltenyi Biotec). At day 7 of culture, cells were
washed and seeded with IL-6 (50 ng/ml; PeproTech), IL-15 (10 ng/ml;
PeproTech), and IFN-a (500 U/ml; R&D Systems) for 3 d.
Flow cytometry
FACS staining was external unless otherwise specified. Cells were stained
with a Live/Dead fixable near-IR dead cell stain kit, for 633 or 635 nm
excitation (Invitrogen). For internal staining, cells were fixed with 2%
formaldehyde (Sigma-Aldrich) and permeabilized with (310) permeabiliza-
tion buffer (eBioscience, Hatfield, U.K.). The following Abs were used for
flow cytometric analysis: anti–CD4-PerCp-Cy5.5 (RPA-T4), anti–CD19-
Pacific Blue (HIB19), anti–CD38-PerCP-Cy5.5 (HIT2), anti–IgD-FITC
(IA6-2), anti–CXCR5-Pacific Blue (J252D4), anti–CD27-PE-Cy7 (M-T271),
anti–CD34-FITC (561), anti–CD68-allophycocyanin (Y1/82A), anti–CD83-
BV421 (HB15e), anti–ICOS-allophycocyanin (C398.4A) (BioLegend,
London, U.K.), anti–CD20-Pacific Orange (HI47, Life Technologies,
Paisley, U.K.), anti–CD138-allophycocyanin (B-A38, Beckman Coulter),
anti–CD10-PE-Cy7 (HI10a), anti–CD45-RA-FITC (T6D11), anti–CD161-PE
(191B8), anti–IgM-allophycocyanin (PJ2-22H3), anti–CXCR4-allophycocyanin
(12G5, Miltenyi Biotec), anti–CD3-FITC (ICHT1, R&D Systems),
anti–LLT1-PE (402659, R&D Systems), anti–IgG isotype control-PE, IgG1
and IG2A isotype controls (R&D Systems), and anti–mouse IgG-PE (R&D
Systems).
Novel mouse anti-human CLEC2D (LLT1) mAbs were generated, in-
cluding clones 359.7G7 (mIgG1) and 359.2H7 (mIgG2al). All purified Abs
are dialyzed against PBS, are low in endotoxin (,2 endotoxin units/mg),
and are filtered sterile.
Immunohistochemistry
Tissue deparaffinization was performed using Histo-Clear (National Di-
agnostics, Hull, U.K.) and ethanol (Sigma-Aldrich; 100, 90, and 70%).
Heat-mediated Ag retrieval was achieved using Dako target retrieval so-
lution (Dako, Ely, U.K.). Endogenous peroxidase activity was blocked using
3% H2O2 (5 min 3 2; Alfa Aesar, Heysham, U.K.) and 0.1% sodium azide
(15 min; Sigma-Aldrich) in water. Nonspecific binding was blocked with
0.5% blocking reagent (PerkinElmer, Beaconsfield, U.K.) in PBS.
Cy5/fluorescein stains were amplified using amplification reagents
(PerkinElmer) diluted in tyramide amplification buffer (12 ml 500 mMTris,
18 ml H2O, 20 mg imidazole [Sigma-Aldrich], 1 ml H2O2). Residual
peroxidase activity was blocked by incubating the slides in 3% H2O2 and
then 0.1% sodium azide in water. Slides were mounted with ProLong Gold
antifade reagent with DAPI (Invitrogen).
A goat polyclonal anti-LLT1 Ab (AF3480, R&D Systems) and a novel
mouse mAb (7G7) were used for immunohistological staining, as well as
CD3 (clone LN10, Leica Microsystems, Cambridge, U.K.) and PAX-5
(clone 24, BD Biosciences, Oxford, U.K.).
Anti-CD161 (B199.2, AbD Serotec, Kidlington, U.K.; 1:100), IgG1, or
IgG2A isotype controls (R&D Systems) were also used and incubated
overnight at 4˚C and then incubated with anti-goat/mouse polymer (Vector
Laboratories, Peterborough, U.K.) HRP conjugated (Vector Laboratories),
followed by ImmPACT diaminobenzidine peroxidase substrate (Vector
Laboratories). The section was covered with hematoxylin (Vector Labo-
ratories) and washed.
In addition to these stains, the following Abs were used for fluorescence
immunohistochemistry: anti-LLT1 goat polyclonal (AF3480, R&D Systems,
1:200), anti-CD68 (1:200, clone PG-M1), anti-FDC (1:100, clone CNA.42),
anti-CD19 (1:500, clone LE-CD19), anti-CD20cy (1:1000, clone L26), anti-
CD3 (1:200, clone F7.2.38), anti-CD79a (1:200, clone JCB117), anti-CD45
(1:1000, clone 2B11 plus PD7/26), anti-IgG (1:1000, rabbit), anti-IgM
(1:1000), anti-CD38 (1:200, clone At13/5), anti-CD138 (1:100, clone
MI15), anti-Ki67 (1:200, clone MIB-1), and anti–IFN regulatory factor
(IRF) 4 (1:200, clone MUM1) (Dako); anti–cathepsin G (1:1000), anti-IgD
(1:200), anti-IgA (1:300) (Leica Biosystems, Newcastle upon Tyne, U.K.);
anti-IgE (rabbit, Abcam, Cambridge, U.K.), and normal goat IgG and mouse
IgG1/IgG2A isotype controls (R&D Systems). Abs were mouse derived
unless otherwise specified.
For the FDC and CD161 costaining in frozen tonsils, four different anti-
CD161 Abs were used: 191B8 (Miltenyi Biotec), IMG141F1F1 (Abcam),
B199.2 (AbD Serotec), and HP-3G10 (BioLegend). Ten-micrometer-thick
frozen tonsillar sections were labeled with 10 mg/ml goat anti-LLT1 (R&D
Systems, AF3480-SP), mouse anti-CD161 (Abcam, ab23624), and rabbit
anti-CD3 (Dako, A0452), followed by 10 mg/ml donkey anti–goat-Alexa
Fluor 488, donkey anti–mouse-Alexa Fluor 594, and donkey anti–rabbit-
Alexa Fluor 647 (Jackson ImmunoResearch, Suffolk, U.K.), respectively,
and peanut agglutinin (PNA; Vector Laboratories, Peterborough, U.K.).
B cell activation
Isolated B cells were stimulated with oligodeoxynucleotide 2006 (CpG,
InvivoGen, Wiltshire, U.K.) for 48 h. TLR signaling inhibition studies used
the MyD88 inhibitory peptide Pepinh-MYD at the given concentration
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(InvivoGen). B cell stimulations were achieved using goat anti-human
IgM/G/A F(ab9)2 (Jackson ImmunoResearch) fragments at 1 mg/ml,
anti-CD40 (clone S2C6, Macbeth) at 5 mg/ml, or with IL-4 (Pepro-
Tech), IL-10, IL-21 (Miltenyi Biotec), PGE2 (Sigma-Aldrich), IL-15
(Miltenyi Biotec), and BAFF (Miltenyi Biotec) (all at 50 ng/ml). Pro-
liferations assays were performed using a CellTrace Violet (CTV) cell
proliferation kit (Life Technologies).
The CD161 blocking assay included 2 3 106 B cells/ml in 500 ml in a
48-well plate (Corning) with combinations of CpG (5 mM), anti-CD40
(5 mg/ml) plus IL-4 (50 ng/ml), anti-CD161 at 1 mg/ml (clone 191.B8,
Miltenyi Biotec), and IgG2A isotype control (R&D Systems).
For LLT1 crosslinking, recombinant CD161 (R&D Systems) or IgG1
isotype control (R&D Systems) were bound to a 96-well ELISA plate
(Greiner Bio-One, Stonehouse, U.K.) overnight prior to the addition of
B cells and BCR stimulus as described above.
Proliferation assay
Proliferation assays were performed using a CTV cell proliferation kit (Life
Technologies). Purified B cells were stained with 2.5 mM CTV for 10 min
at room temperature, following the manufacturer’s instructions. Cells were
then counted and 2 3 105 B cells were plated per well in a U-bottom
96-well plate with CpG (0.5 mg/ml) for 5 d.
CD161 depletion
Tonsillar cells were stained with CD161-PE (Miltenyi Biotec) and depleted
from the sample by FACS sorting using a MoFlo (Beckman Coulter). After
CpG (0.5 mM, InvivoGen) or anti-CD40 (5mg/ml, Macbeth) plus IL-4
stimulation (50 ng/ml, PeproTech), levels of CD38 and CD83, respec-
tively, were measured in alive CD19+ cells.
Real-time PCR
For real time RT-PCR, amplification was assessed using molecular probes 32
(for CD161) and 60 (for GAPDH) from the Universal ProbeLibrary set, human
(Roche, Welwyn Garden City, U.K.) on a LightCycler 480 (Roche). The
following primers were used: CD161, forward, 59-AAATGCAGTGTGGA-
CATTCAA-39, reverse, 59-CTCGGAGTTGCTGCCAATA-39 (Eurofins MWG
Operon, Ebersberg, Germany); GADPH, forward, 59-AGCCACATCGCTCA-
GACAC-39, reverse, 59-GCCCAATACGACCAAATCC-39; CXCR4, for-
ward, 59- GGTGGTCTATGTTGGCGTCT-39, reverse, 59-ACTGACGTT-
GGCAAAGATGA-39 (Eurofins MWG Operon, Germany).
Data acquisition and analysis
FACS analysis was performed on Miltenyi Biotec MACSQuant cytometer
and analyzed with FlowJo version 9.6.2 software (Tree Star, Ashland, OR).
Graphs and statistical analysis were performed using GraphPad Prism
version 6.0a (GraphPad Software, San Diego, CA).
For analysis of immunohistochemical staining, images were acquired on
a DSS1 Coolscope slide scanner (Nikon, Kingston upon Thames, U.K.).
For immunofluorescent microscopy, images were acquired on an
Olympus Fluoview FV1000microscope (Olympus, Southend-on-Sea, U.K.)
and analyzed using Fiji (ImageJ, National Institutes of Health, Bethesda,
MD). The Leica TCS-SP2 AOBS confocal laser-scanning microscope was
used for the CD161 immunofluorescence, and the images were captured and
processed with Leica confocal software (LCS Lite) and ImageJ.
Results
LLT1 is highly expressed on GC B cells
LLT1 expression was observed within normal human tonsils and
predominantly expressed within GCs (Fig. 1A). This was demon-
strated by immunohistological staining using two independent Abs: a
commercial goat polyclonal anti-LLT1 Ab, and a novel anti-LLT1 Ab
(clone 7G7, see Materials and Methods, Supplemental Fig 1A, 1B).
Furthermore, this was not restricted to tonsillar tissue, as GCs
within spleen, lymph nodes, and Peyer’s patches were also LLT1+
(Supplemental Fig. 1C–F).
LLT1 expression within GC cells was restricted to PAX-5+ cells,
B cells (Fig. 1B). Intra-GC T cells (Fig. 1B), tingible body macro-
phages, neutrophils, and FDCs within secondary follicles were all
negative for LLT1 (data not shown). However, within the inter-
follicular areas, LLT1 expression was seen on a small proportion of
CD3+ T cells (Fig. 1B, inset). Furthermore, LLT1 expression on GC
B cells was confirmed by costaining for CD20 (Fig. 1C), Ki67
(Fig. 1D), and CD38 (Fig. 1E). FACS analysis, using a second novel
anti-LLT1 Ab (clone 2H7), also confirmed LLT1 on GC B cells,
defined as CD38midIgD2, as previously described (25–27) (Fig. 1F).
LLT1 expression was not homogeneous throughout the GC.
A clear difference in LLT1 staining intensity could be seen
by immunohistology. Cross-sectional analysis through the GC
revealed increased LLT1 levels within the DZ compared with the
LZ (defined by the presence of CD3+ cells, stained green, Fig. 1G).
Moreover, FACS analysis confirmed higher LLT1 expression
on DZ B cells (CD83lowCXCR4high) compared with LZ B cells
(CD83highCXCR4low) (Fig. 1H).
LLT1 is expressed on plasmablasts but not memory B cells
B cells exit the GC upon differentiation into plasma or memory B cells.
Whether LLT1 expression is maintained in these GC B cell derivatives
is not known; therefore, we sought to track LLT1 expression through
these stages. Plasmablasts were identified by costaining tonsillar
sections with LLT1 plus CD19, CD20, CD38, CD45, CD79a, CD138,
IRF4 (MUM-1), and Igs (Fig. 2A). LLT1+ cells coexpressed these
markers in a pattern suggestive of a plasmablast phenotype (CD45low,
CD202, CD19low, CD79a2/low, pan Ig+, MUM-1+/2, CD38+, Ki67+/2,
CD1382), although there remained a number of LLT1+ cells that did
not fit this phenotype and remain to be identified.
FACS analysis, using the Bm1–Bm5 classification based on
CD38 and IgD markers (Fig. 2B), revealed that LLT1 expression
was restricted to GC B cells, pre-GC B cells, and plasmablasts
within tonsillar-derived cells (Fig. 2C) and plasmablasts within
PBMCs (Fig. 2D) (25, 26, 28). The IgD+CD38low compartment,
comprising both naive and transitional B cells, were mainly
negative for LLT1 (Fig. 2C, 2D) (29). As plasmablast frequencies
are normally low in circulation, we also confirmed LLT1 ex-
pression on plasmablasts in individuals 1 wk postvaccination,
where plasmablasts are readily detectable (30, 31) (Fig. 2E). LLT1
expression, however, was not detected on plasma cells or memory
B cells (Fig. 2A–C).
To confirm that LLT1 is downregulated as plasmablasts mature into
plasma cells, we differentiated CD27+ memory B cells into plasma-
blasts and then plasma cells in vitro, as described by Jourdan et al.
(24). LLT1 expression was measured by FACS analysis at days
0 (memory B cells), 4 (early plasmablasts), 7 (late plasmabalsts), and
10 (plasma cells) (Fig. 2F). Day 0 resting CD27+ memory B cells
expressed very low levels of LLT1, but LLT1 was highly upregulated
at day 4 on early plasmablasts, but downregulated at further stages of
differentiation (Fig. 2G). Additionally, we confirmed the absence of
LLT1 on plasma cells in vivo by FACS and immunohistological
staining of long-lived, bone marrow–resident CD138+ cells from
bone marrow samples (data not shown).
Given access to bone marrow samples, we took the opportunity
to assess expression levels of LLT1 on the early developmental
stages of B cells; thus, we were able to assess LLT1 expression
throughout the whole life of a B cell (Supplemental Fig. 2).
Regulation of LLT1 expression on memory B cells
Next we questioned how LLT1 was regulated within B cells. Pre-
vious work has shown LLT1 can be upregulated following TLR9,
BCR, and CD40 stimulation (21). We confirmed CpG-induced ex-
pression (Fig. 3A) and extended this to show that this mechanism is
MyD88-dependent, as the presence of the MyD88 inhibitor, Pepinh-
MYD, blocked upregulation (Fig. 3B). In addition to CpG, we
explored the kinetics of both BCR and CD40 stimulation to induced
LLT1 expression. BCR signaling in isolated PBMC-derived mem-
ory B cells induced a maximum expression after 5 d (Fig. 3C),
whereas CD40 stimulation induced LLT1 expression within 2 d
(Fig. 3D). Furthermore, B cell activation is associated with a broad
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range of cytokines; therefore, we assessed the ability of IL-4,
IL-10, IL-21, PGE2, IL-15, and BAFF to upregulate LLT1. None
of the cytokines tested was able to induce LLT1 expression
(Fig. 3E) (32–35).
Interestingly, LLT1 expression was associated with early rounds
of proliferation after CpG stimulation, increasing with each divi-
sion until the third, were it plateaued (Fig. 3F). This is consistent
with the observation of high LLT1 expression within DZ B cells
(Fig. 1G, 1H), plasmablasts (Fig. 2), and B cell lymphomas (see
Fig. 6).
CD161 is expressed on FDCs and on a subset of tonsillar
T cells
Before we addressed the function of LLT1, we looked for the
expression of the LLT1 ligand, CD161, within the context of the
GC. CD161 expression has been described on both NK cells and
T cells. Therefore, T follicular helper (Tfh) cells were an obvious
candidate cell type, with a potential to interact with GC B cells.
Flow cytometric analysis of tonsillar T cells revealed a loss of
CD161 expression as the Tfh cells progressed to full GC phenotype,
as defined by CXCR5 expression (36) (Fig. 4A, top right panel).
This was confirmed at the mRNA level in sorted tonsillar T cells
(Fig. 4A, bottom right panel). Although a small fraction (,10%)
of CXCR5high Tfh cells expressed CD161, they were not observed
within any of the GCs assessed by immunofluorescence micros-
copy (Fig. 4B, Supplemental Fig. 3). Similarly, within the
PBMCs, circulating Tfh cells (defined simply as CXCR5mid) (37)
also had lower frequencies of CD161+ cells compared with the
CXCR52 fraction (Supplemental Fig. 3).
Next, CD161 expression was assessed on tonsillar macrophages
(including tingible body macrophages), defined by CD68 expres-
sion; however, no expression was observed (Supplemental Fig. 3).
Unexpectedly, immunofluorescence staining of human tonsils
revealed the expression of CD161 on FDCs (Fig. 4C). Costaining
of CD161 and a FDC marker (CNA.42 clone) showed a strong
overlap, with a typical stain pattern associated with FDCs. This
striking finding was confirmed by histological staining and was
not specific to just one clone of anti-CD161 Ab (Supplemental
Fig. 3). Costaining of PNA, LLT1, and CD161 showed interaction
between LLT1 on GC B cells and CD161, expressed in a FDC
pattern, within the GC (Fig. 4D).
LLT1 promotes B cell activation and downregulation of
CXCR4 in GC B cells
Interactions between FDCs and B cells are complex, involving a
wide range of receptors (38). Binding of BCRs to Ags, presented
FIGURE 1. LLT1 is expressed on GC B cells. (A) Expression of LLT1 (brown), using the 7G7, was assessed in formalin-fixed, paraffin-embedded human
tonsillar tissue sections (original magnification 340) (representative of five sections). (B) Triple staining for LLT1 (membrane and cytosol brown), CD3
(membrane pink), and PAX-5 (nuclear blue) showed LLT1 (goat-polyclonal, brown) strongly associated with PAX-5 and only rarely with CD3 (arrow in
inset) (original magnification 320, inset 360). Costaining of LLT1 (goat-polyclonal) with CD20 (C), Ki67 (D), and CD38 (E) (scale bar, 100 mm, rep-
resentative of three sections). (F) FACS analysis of LLT1 expression on naive (blue), memory (orange), and GC (green) B cells (representative plot of five
independent experiments). (G) Cross-sectional analysis through a region (yellow band) of a GC (green indicates CD3, red indicates LLT1; representative of
three independent experiments). Geometric mean fluorescence intensity (geoMFI) of LLT1 expression within the defined yellow region plotted against pixel
count; the LZ (green) and DZ (red) regions are highlighted. (H) FACS analysis of LLT1 (2H7 clone) on LZ and DZ, CXCR4 and CD83, respectively (*p ,
0.05, nonparametric paired t test).
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by the FDC, and of CD40 to CD40L delivers crucial signals re-
quired for B cells to progress to the next stage of the GC reaction
and interact with Tfh cells, and subsequently go on to re-enter the
DZ (10, 39–41).
As B cell–FDC interactions involve many different ligands and
receptors, we explored the role of LLT1 in isolated B cells. Ini-
tially, we investigated LLT1 signaling in primary B cells, inducing
LLT1 expression through stimulation with anti-BCR, as described
above, with and without rCD161 protein or a control protein (IC).
After 5 d of stimulation, B cell expression of CD83 and CD38
was measured by flow cytometry. Triggering of LLT1 on B cells
through rCD161 resulted in increased B cell activation. Signifi-
cantly higher increases in CD83 and CD38 were seen on B cells in
the presence of rCD161 compared with the controls (Fig. 5A).
As both proteins are highly glycosylated and have a weak
binding strength (Kd of 48 mM), we addressed whether binding of
naturally expressed LLT1–CD161 would reveal stronger signaling
(42). To analyze this, we cultured tonsillar cells, which included
both B cells and CD161+ cells, for 3 d with either anti-CD40 plus
IL-4 or CpG and assessed their activation state by flow cytometry
on day 3. The effect of LLT1 signaling was measured through the
use of blocking Abs to CD161 (Fig. 5B, left panel). Stimulation of
B cells with anti-CD40 plus IL-4 resulted in a striking upregula-
tion of CD83 on day 3, which was significantly inhibited by the
addition of the anti-CD161 Ab. This was not observed with the
CpG-stimulated sample. In contrast, levels of CD38 expression
were highly increased upon CpG stimulation. Once again, the
addition of the anti-CD161 blocking Ab significantly reduced
CD38 upregulation (Fig. 5B, right panel). Furthermore, depletion
of CD161+ cells from the cellular cultures, prior to stimulation
with either anti-CD40 plus IL-4 or CpG, also resulted in a sig-
nificant decrease in CD83 and CD38 expression, respectively
(Fig. 5C, left panel for anti-CD40 plus IL-4 stimulation and right
panel for CpG stimulation).
Finally, we explored the functional consequences of LLT1
triggering on GC B cells. The presence of rCD161 or the cross-
linking anti-LLT1 Ab (2H7) did not have an impact on CD83
expression levels (Fig. 5D), CD38, or survival (Supplemental Fig.
4); however, LLT1 signaling resulted in a significant reduction of
CXCR4 (Fig. 5E). This was also analyzed on sorted DZ B cells,
where the effect of LLT1 crosslinking resulted in the downregu-
lation of CXCR4 at mRNA level (Fig. 5F).
These findings suggest that LLT1 is involved in the transition of
DZ B cells to the LZ through the downregulation of CXCR4,
while contributing to enhanced levels of CD83 expression.
LLT1 is expressed in human B cell lymphomas
As a site of mutation and proliferation, many B cell lymphomas are
derived from the GC. Therefore, having established LLT1 ex-
pression on GC B cells in vivo under normal conditions, we next
FIGURE 2. LLT1 is expressed on early plasmablasts. (A) Costainings in formalin-fixed, paraffin-embedded human tonsillar tissue of LLT1 with
CD20 (original magnification 310), CD19 (original magnification 320), CD45 (original magnification 310), CD79a (original magnification 320), CD38
(original magnification 320), CD138 (original magnification 320), Igs (original magnification 320), Ki67 (original magnification 320), and IRF4
(original magnification 310). White arrows indicate double-positive cells (scale bars, 100 mm), representative of three independent sections. (B) Seven
different B cell subsets identified by IgD and CD38 expression in tonsillar tissue (top) and PMBCs (bottom): virgin naive (VN), activated naive (AN), pre-
GC, early memory (EM), late memory (LM), and plasmablasts (PB) are shown. Geometric mean fluorescence intensity (geoMFI) of LLT1 was measured in
the subsets: tonsils (C, n = 10) and blood (D, n = 3). (E) Expression of LLT1 in the plasmablast subset in an example vaccinated individual 1 wk post-
immunization, representative of eight similar individuals. (F and G) LLT1 expression in in vitro–generated plasmablasts analyzed on day 0, day 4 plas-
mablasts (PB), day 7 PB, and day 10 plasma cells (PC). (F) Representative FACS plot of time course. (G) Graphed data pooled from three independent
experiments (total n = 6).
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examined whether such linked expression was maintained in the
context of neoplasia. We assessed LLT1 expression in five B cell
lymphoma cell lines. FL18, KHM2, L421, and SUDHL6 were
positive for LLT1, whereas Burkitt’s lymphoma–derived Namalwa
cells where negative (data not shown). Using a commer-
cially available LLT1 Ab (goat polyclonal, see Materials and
Methods), LLT1 expression was evaluated in a series of lymphomas
(Fig. 6A–E). LLT1 was absent on non-GC–derived lymphomas,
such as B-ALL and plasma cell neoplasms. In contrast, LLT1
expression was seen on most Burkitt lymphomas (14 of 19,
73.68%), follicular lymphomas (48 of 95, 51%), and also on
Hodgkin lymphomas (7 of 16, 44%). Subdivision of the follicular
lymphomas revealed the highest association of LLT1 on atypical
phenotypes that have been previously described: Bcl-22 (59%)
FIGURE 3. LLT1 is upregulated with CpG, anti-
BCR, and anti-CD40 stimulation. (A) Purified B cells
from PBMCs were stimulated with increasing concen-
trations of TLR9 agonist CpG for 48 h, which resulted
in a dose-dependent increase in the percentage of
LLT1-expressing B cells (2H7 clone). (B) The effect
was blockable with MyD88 inhibitor, Pepinh-MYD,
and it was also dose-dependent. (C) BCR stimulation
resulted in upregulation of LLT1 on B cells. (D) LLT1
was also upregulated on B cells upon CD40 stimula-
tion. (E) Stimulation with different cytokines (50 ng/ml
for 48 h) did not alter expression levels of LLT1 on B
cells. (F) B cell proliferation, measured by CTV dilu-
tion, after 5 d with CpG stimulation (0.5 mM). LLT1
increased in successive rounds of proliferation and
reached a plateau. Representative plots of three inde-
pendent experiments are shown.
FIGURE 4. CD161 is expressed on
FDCs and on a subset of tonsillar
T cells. (A) CD161 expression nega-
tively correlated with CXCR5 ex-
pression on CD45RA2 T cells (CD3+
CD4+) assessed by FACS (n = 5,
three independent experiments) and
real-time PCR (n = 3, two indepen-
dent experiments). (B) Costaining of
CD161 and CD3, showing no double-
positives within the GC. Original
magnification 320. (C) Immuno-
fluorescence staining of frozen hu-
man tonsils with an FDC marker
(clone CNA.42) and CD161 (clone
IMG14F1F11) showed complete
overlap between these two markers.
Original magnification 320. (D)
Triple FDC, LLT1, and PNA stain of
a frozen tonsillar human section. In-
teraction between FDCs and double-
positive LLT1-PNA GC B cells can
be observed (red square). Represen-
tative image of six different follicles.
Original magnification 363 oil ob-
jective with 33 digital zoom.
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and Bcl-22 and CD102 (62%) (Fig. 6F, lower left panel) (43).
Interestingly, LLT1 expression was seen on lymphocyte-
predominant Hodgkin lymphomas and not classical Hodgkin
lymphomas (Fig. 6F, lower right panel). Our data suggest that
LLT1 is maintained during malignant transformation in some
GC-derived lymphomas and may be a useful additional diag-
nostic marker.
Discussion
GC were first characterized .125 years ago. In recent years, our
understanding of how these dynamic and complex reactions are or-
chestrated has advanced rapidly. In this study, we report the expres-
sion and function of the innate receptor pairing, LLT1 and CD161,
within the GC reaction in humans.
A GC can be divided into two microanatomically distinct regions,
the LZ and the DZ. Competition for Ag and Tfh cell help occurs
within the LZ, whereas somatic hypermutation and proliferation
are restricted to the DZ (reviewed in Ref. 40).
Although LLT1 expression was marginally higher on DZ cells, it
was observed on all GC B cells in all lymphoid tissues tested. LLT1
expression was not, however, restricted just to GC B cells, as LLT1+
cells were detected outside of the GC. Many of these cells expressed
markers associated with a plasmablast phenotype (CD45low, CD202,
CD19low, CD79alow, Ig+, IRF+, CD38+, Ki67+, CD1382), although
this does not exclude other cell types. In vitro differentiation of
memory B cells into plasmablasts and then plasma cells demonstrated
that LLT1 expression was lost as cultures progressed toward termi-
nally differentiated plasma cells at day 10 (24). This was also con-
firmed on staining bone marrow–derived plasma cells. It appears that
LLT1 expression on plasmablasts in vivo is a marker of recent exit
from the GC, although whether it can also be independently upreg-
ulated remains to be addressed.
It was noted that LLT1 was frequently associated with dividing
cell populations both in vivo and in vitro. Zhou et al. (23) also
observed that OCIL (LLT1) mRNA expression was at its highest
during the osteoblast proliferative phase of bone marrow cultures.
In contrast, we observed that LLT1 was absent from plasma cells
and both early and late memory B cells, which are nondividing
cells. This suggests a link between proliferation and LLT1 ex-
pression, although we have not as yet been able to find any
functional involvement of LLT1 during proliferation (data not
shown). However, LLT1 might be a useful marker for the identi-
fication of GC B cells with high-affinity BCRs, as B cells with
high-affinity BCRs are able to more efficiently present Ag to Tfh
cells and consequently undergo more rounds of division (44).
To better understand the function of LLT1 within the context of
the GC, we investigated potential sites of interactions by seeking
the expression of its ligand, CD161. Lanier et al. (45) originally
identified the expression of CD161 on both CD4+ and CD8+
T cells, which has been broadened to include innate lymphocyte
FIGURE 5. LLT1 promotes B cell activation. (A) Purified B cells from PBMCs were stimulated with anti-BCRs only or with anti-BCRs with and without
rCD161 or IC. Geometric mean fluorescence intensities (GeoMFI) of CD83 and CD38 were measured by flow cytometry. B cell stimulation with rCD161
resulted in enhanced levels of CD83 and CD38; data were pooled from three independent experiments (n = 7, **p, 0.01). (B) Tonsillar cells were cultured
for 3 d with CpG or anti-CD40 plus IL-4. Blocking LLT1–CD161 interaction resulted in a decreased expression of CD83 and CD38 on B cells; data were
pooled from four independent experiments (n = 12, ****p, 0.0001). (C) Depletion of CD161+ cells from tonsillar cells resulted in decreased expression of
CD83 (anti-CD40 plus IL-4 stimulation) and CD38 (CpG stimulation) on B cells after 3 d; data were pooled from two independent experiments (n = 8;
*p , 0.05, ****p , 0.0001, paired t test). (D) Overnight stimulation of tonsillar B cells with rCD161 or 2H7 anti-LLT1 Ab did not change the expression
of CD83 on GC B cells (n = 5). (E) However, a decrease in CXCR4 expression levels was observed GC B cells (n = 10; **p , 0.01, ****p , 0.0001).
(F) Repeated experiments on sorted DZ B cells revealed a downregulation of CXCR4 mRNA. All statistics were two-way ANOVA using a Bonferroni
multiple comparisons test, unless stated otherwise.
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subsets (15, 46–49). However, murine homologs of CD161, NKR-
P1B and NKR-P1D, are not fully analogous, as they differ both in
expression profiles and function (reviewed in Ref. 50).
Unexpectedly, CD161 was observed on FDCs. This was par-
ticularly surprising, as it is uncommon for NK cell receptors to be
expressed on nonhematopoietic cells, although relevant examples
exist, for example, KACL on keratinocytes (51) and LLT1 on
osteoblasts (23).
Given the close association of CD161 expression and T cells,
CD161 expression was also investigated on Tfh cells (CXCR5mid/high).
However, CD161 expression negatively correlated with CXCR5
expression, at both the protein and mRNA levels. A potential
explanation for this may lie in the transcription factor Bcl-6. This
master transcription factor drives maturation of T and B cells
toward a full GC phenotype. As Bcl-6 expression increases it
suppresses other lineage-associated transcription factors, such as
retinoic acid–related orphan receptor gT, a transcription factor
associated with CD161 expression (46, 52–54). Thus, it is plau-
sible that Bcl-6 inhibits the expression of CD161 through the
suppression of retinoic acid–related orphan receptor gT.
The LZ and DZ can be identified by the higher expression of
either CD83 or CXCR4, respectively (1, 3, 55–57). Movement
between the zones is fundamental for efficient participation within
the GC reaction (3, 44, 58). Entry into the DZ requires Tfh in-
teractions and the expression of CXCR4, although CXCR42/2
B cells are still able to transit into a centroblast phenotype and
acquire mutations, albeit at a lower level compared with their
wild-type counterparts (3, 44, 58). Migration back to the LZ is
associated with lower CXCR4 expression, but the underlying
mechanisms have not been identified. In this study, crosslinking of
LLT1 alone resulted in a reduction in the expression of CXCR4 in
DZ B cells. Therefore, these data suggest that LLT1 triggering
occurs within the LZ.
Once within the LZ, B cells interact with FDCs and Tfh cells and
receive a number of costimulatory signals (59–62). A key receptor
in these interactions expressed by the B cells is CD83 (63–65).
Triggering of LLT1 alone did not alter the expression of CD83 GC
B cells. However, in the context of BCR or CD40 signaling, LLT1
triggering promoted CD83 expression. This suggests that LLT1
may also help enhance B cell interactions with both FDCs and Tfh
cells. Combined with the downregulation of CXCR4, these data
suggest that LLT1 triggering helps drive B cells through the dif-
ferent GC transitional states within the LZ (57).
LLT1’s high expression within the GC, and its association
with proliferating cells, suggests its use as a potential aid for the
clinical diagnosis of B cell lymphomas, in particular non–Hodgkin
lymphomas, which represent 4–5% of all cancers diagnosed (66).
Treatment selection relies on accurate diagnosis, staging of the
disease, and identification of adverse prognostic factors. Expres-
sions of Bcl-6, CD10, and IRF4 are used in immunohistochemical
stains to separate diffuse large B cell lymphomas into GC and
non-GC subtypes (67, 68). However, although immunohisto-
chemistry is widely used, it is not always reliable, in particular
when identifying follicular lymphomas with atypical phenotypes.
FIGURE 6. LLT1 is expressed in human B cell lymphomas. (A–E) Representative stainings of LLT1 (membrane and cytosol brown) as assessed
(polyclonal Ab AF3480) in formalin-fixed, paraffin-embedded tissue sections of follicular lymphoma samples [(A) original magnification 340; (B) original
magnification 310], lymphocyte-predominant Hodgkin lymphoma [(C) original magnification 340; arrow and inset highlighting LLT1+ staining,
original magnification 360], classical Hodgkin lymphoma [(D) original magnification 340; arrow and inset highlighting LLT1+/2 staining, original
magnification 360], and Burkitt lymphoma [(E) original magnification 340]. (F) The percentage of LLT1+ lymphomas was assessed by immunohisto-
chemistry in different B cell non-Hodgkin lymphomas, T cell non-Hodgkin lymphomas, and Hodgkin lymphomas. cHL, classical Hodgkin lymphoma;
LPHL, lymphocyte-predominant Hodgkin lymphoma.
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LLT1, therefore, provides a potential new marker for the clinical
investigation of lymphomas, and it warrants larger prognostic
studies to provide more data on the independent significance of
positive or negative stains.
LLT1 and CD161 are both CLRs encoded within the NKC,
located adjacent to one another (4–7, 51, 69). Expression of other
NKC proteins within the GC is limited to CD69 on both B cell and
Tfh cells; however, a function for CD69 within the GC has not
been described. The role of particular lectins in the modulation of
BCR responses has been explored before. For instance, CD22 and
CD72 have been shown to downmodulate BCR-mediated signals
(70). Furthermore, the C-type lectin CD23, the low-affinity re-
ceptor for IgE, is also relevant in the context of B cell responses
(71), as it acts as a ligand for CD21 within the BCR complex.
Interestingly, CD23 has been found highly expressed in a pro-
portion of FDCs. Thus, the data presented in this study are con-
sistent with a contribution of C-type lectins to B cell responses
through FDC–B cell interactions. This is particularly meaningful,
as CLRs, once thought to be essentially involved in innate im-
munity, have now been shown to play a prominent role in the GC
reaction, a hallmark of adaptive immunity.
The data presented in the present study suggest a role for innate
components of the human immune system, such as LLT1 and
CD161, in the GC reaction. Our data suggest that LLT1 triggering
may play a key role in the GC reaction promoting B cell activation
and downregulating CXCR4, thus helping to promote an LZ
phenotype and facilitating both FDC and Tfh interactions.
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	 1	
SUPPLEMENTAL FIGURES 1	
 2	
Figure S1. Germinal Centers of different secondary lymphoid organs are all 3	
positive for LLT1. (A) shows specific staining of the 2H7 and 7G7 clones using 4	
transfected human LLT1 300 cells.  (B) Western blot assessment of 7G7 antibody 5	
specificity against a range of cell lines, the 2H7 clone was not functional by western 6	
blots (data not shown). (C-F) Tissue sections stained for LLT1 using the polyclonal 7	
goat anti-LLT1 (AF3480) antibody: (C) (x40) composite image from a lymph node, 8	
(D) tonsil (x20),  (E) (x10) appendix, (F) spleen (x20), arrows point LLT1+ cells 9	
outside the germinal center.10	
	 2	
 11	
Figure S2. LLT1 is expressed in the stages of pre-GC, GC B cells and 12	
plasmablasts. LLT1 levels were analysed by FACS (2H7 clone) in different stages of 13	
B cell differentiation, using samples from bone marrow and tonsils. Pre-Pro B 14	
(CD10+ CD19-  CD34+ IgM-), Pro-B (CD10+ CD19+ CD20- CD34+ IgM-), Pre-B 15	
(CD19+ CD20+ CD34-IgM-), Immature (CD10+ CD19+ CD20+ IgM+), Transitional 16	
(CD19+ CD20+ IgM++), Virgin naive (CD19+ IgD+ CD38-), Activated naive 17	
(CD19+ CD38+ IgD+), Pre-GC (CD19+, CD38++, IgD+), GC (CD19+ CD38 ++ 18	
IgD-), PB (CD19low, CD38+++, IgD-), PC (CD19low CD138+ IgD-), Early memory 19	
(CD19+ CD38+ IgD-) and late memory (CD19+ CD38- IgD-). LLT1 was not 20	
expressed on B cell precursors or transitional B cells, nor in tonsillar naive B cells. 21	
However, LLT1 was highly expressed in pre-GC and GC B cells from tonsils. Its 22	
levels remained high in plasmablasts but were quickly downregulated in memory B 23	
cells. Terminally differenatiated plasma cells did not express LLT1. (Bone marrow 24	
n=5; Tonsils n=10).25	
	 3	
 26	
 27	
Figure S3. CD161 is expressed in the germinal center environment. (A) CD68 28	
staining showed no expression CD161 macrophage (including the TBM population). 29	
(B) CD161 expression was lower on CXCR5+ CD4+T cells from both tonsils and 30	
PBMC. (C) Staining with anti-CD161 antibody (brown; B199.2 clone) of FFPE 31	
human tonsillar tissue (CD161 20x, Isotype control 10x) revealed an expression 32	
pattern similar to the one of FDCs. Representative images of one out of 3 independent 33	
experiments are shown. (D) Immunofluorescent staining of frozen human tonsils with 34	
the FDC marker and different anti-CD161 antibody clones (191B8, B199.2 and HP-35	
3G10) revealed expression of CD161 on FDCs. 36	
	 4	
 37	
Figure S4. Controls for Figure 5. (A) The percentage of live GC B cells after 38	
overnight stimulation is shown. Purified B cells from tonsils were incubated with 39	
rCD161, 2H7 antibody or isotype control (n=10). No significant (ns) differences were 40	
detected between any of the groups (two-way ANOVA using a Bonferroni multiple 41	
comparisons test). (B) Sorted DZ and LZ B cells (Alive CD19+, CD83high/low 42	
CXCR4high/low) were rested overnight and the percentage of live B cells measured 43	
by flow cyometric analysis (n=7). No significant differences could be detected (non-44	
parametric paired T-test). (C) Purified B cells from tonsils were incubated with 45	
rCD161, 2H7 antibody or isotype control, and levels of CD38 expression measured by 46	
flow cytometry (n=10). No significant differences were detected between any of the 47	
groups (two-way ANOVA using a Bonferroni multiple comparisons test). 48	
